2025
Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial
Somé A, Somé A, Sougué E, Ouédraogo C, Da O, Dah S, Nikièma F, Magalhaes T, Gray L, Finical W, Pugh G, Lado P, Randall J, Burton T, Ring M, Leon A, Colt M, Li F, Wang K, Wade M, Lier A, Richards K, Sproch H, Zhang E, Ellman J, Achebe I, Jackson C, Xiao M, Wu E, Bousema T, Slater H, Foy B, Parikh S, Dabiré R. Safety and efficacy of repeat ivermectin mass drug administrations for malaria control (RIMDAMAL II): a phase 3, double-blind, placebo-controlled, cluster-randomised, parallel-group trial. The Lancet Infectious Diseases 2025 PMID: 39919778, DOI: 10.1016/s1473-3099(24)00751-5.Peer-Reviewed Original ResearchSeasonal malaria chemopreventionIvermectin mass drug administrationEntomological inoculation rateMalaria incidenceParallel-group trialMass drug administrationDouble-blindPlacebo-controlledControl groupAdverse eventsPrimary outcomeWeekly active case detectionDrug AdministrationLow malaria incidenceIntervention groupReducing malaria incidenceMalaria-endemic regionsMalaria incidence ratesRisk of adverse eventsInoculation rateNational Institute of AllergyPan African Clinical Trials RegistryComplementary vector control toolsCluster-randomisedInstitute of Allergy
2024
Two Mosquito Salivary Antigens Demonstrate Promise as Biomarkers of Recent Exposure to Plasmodium falciparum–Infected Mosquito Bites
Lapidus S, Goheen M, Sy M, Deme A, Ndiaye I, Diedhiou Y, Mbaye A, Hagadorn K, Sene S, Pouye M, Thiam L, Ba A, Guerra N, Mbengue A, Raduwan H, Gagnon J, Vigan-Womas I, Parikh S, Ko A, Ndiaye D, Fikrig E, Chuang Y, Bei A. Two Mosquito Salivary Antigens Demonstrate Promise as Biomarkers of Recent Exposure to Plasmodium falciparum–Infected Mosquito Bites. The Journal Of Infectious Diseases 2024, 231: e570-e581. PMID: 39475423, PMCID: PMC11911913, DOI: 10.1093/infdis/jiae525.Peer-Reviewed Original ResearchModerate transmission areasMosquito salivary proteinsModerately endemic areaAntibody responseMosquito exposureTransmission seasonP. falciparum infectionMalaria transmission seasonMalaria transmission intensityExposure to infectious mosquitoesMosquito bitesEntomological inoculation rateEndemic areasHuman immune responseInfected mosquito bitesTransmission areasDecline 3 monthsNo antibody responseExposure to infected mosquitoesP. falciparumControl cohortExposure to mosquitoesBead-based assayImmune responseSalivary proteins
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply